9 results on '"Ridolfo, Annalisa"'
Search Results
2. Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice.
- Author
-
Cattaneo D, Baldelli S, Resnati C, Giacomelli A, Meraviglia P, Minisci D, Astuti N, Ridolfo A, De Socio GV, Clementi E, Galli M, and Gervasoni C
- Subjects
- Antidepressive Agents blood, Antidepressive Agents therapeutic use, Antipsychotic Agents blood, Antipsychotic Agents therapeutic use, Female, HIV Seropositivity blood, Humans, Male, Mental Disorders drug therapy, Middle Aged, Psychotropic Drugs therapeutic use, HIV Infections blood, HIV Seronegativity, Psychotropic Drugs blood
- Abstract
Objectives: The management of psychiatric illness in HIV-infected patients is clinically challenging because of the risk of potential drug-drug interactions. Here, we aimed to measure the antidepressant and/or antipsychotic drug concentrations in HIV-infected patients during routine outpatient visits. Methods: Six hundred HIV-infected patients were screened during the first 15 months after the introduction of our outpatient polytherapy management service in a search for subjects treated with psychotropic drugs for at least 3 months. The distribution of psychotropic drug concentrations in HIV-infected patients was compared with that observed in a control group of HIV-negative patients monitored over the same period. Results: The search identified 82 HIV-infected patients concomitantly receiving antiretroviral and psychotropic drug treatment, 55% of whom had plasma psychotropic drug concentrations that were below minimum effective levels. The same result was found in only 26% of the samples taken from HIV-negative patients. These results were not affected by patients' gender, age, adherence to therapies or drug-drug interactions. Conclusions: A higher rate of sub-therapeutic antidepressant and/or antipsychotic drugs concentrations were found in HIV-infected patients. The creation of multidiscliplinary specialist teams may contribute to improving the management of such complex patients.
- Published
- 2020
- Full Text
- View/download PDF
3. Contribution of transgender sex workers to the complexity of the HIV-1 epidemic in the metropolitan area of Milan.
- Author
-
Lai A, Bergna A, Simonetti FR, Franzetti M, Bozzi G, Micheli V, Atzori C, Ridolfo A, Zehender G, Ciccozzi M, Galli M, and Balotta C
- Subjects
- Adult, Aged, Female, HIV Infections virology, Humans, Italy epidemiology, Male, Middle Aged, Molecular Epidemiology, Phylogeny, Sexual and Gender Minorities statistics & numerical data, South America ethnology, Epidemics, Genes, pol genetics, HIV Infections epidemiology, HIV-1 genetics, Heterosexuality statistics & numerical data, Sex Workers statistics & numerical data, Transgender Persons statistics & numerical data
- Abstract
Objectives: Transgender people are disproportionately affected by the HIV-1 epidemic. We evaluated the origin of HIV-1 variants carried by South American transgenders living in Milan by combining accurate phylogenetic methods and epidemiological data., Methods: We collected 156 HIV-1 pol sequences obtained from transgender patients engaged in sex work (TSWs) followed between 1999 and 2015 at L. Sacco Hospital, Milan, Italy. Phylogenetic analyses were conducted by HIV-TRACE, MrBayes, MacClade and Beast programs. Reference sequences were retrieved from Los Alamos and local databases. Last negative testing or proxy data from clinical records of infected individuals were used to investigate the country of infection., Results: Among South American TSWs, the most represented HIV-1 subtypes were B (70.5%), F1 (12.8%) and C (4.4%). Gene flow migrations of B subtype indicated significant fluxes from TSWs to Italians (21.3%) belonging to all risk groups (26.4% to heterosexuals (HEs), 18.9% to men who have sex with men (MSM), 15.1% to injecting drug users). The largest proportion of bidirectional fluxes were observed between Italians and TSWs (24.6%). For F1 subtype, bidirectional viral fluxes involved TSWs and Italians (7.1% and 14.3%), and a similar proportion of fluxes linked TSWs and Italian HEs or MSM (both 15.8%). Significant fluxes were detected from Italians to TSWs for subtype C involving both MSM (30%) and HEs (40%). Country of HIV-1 acquisition was identified for 72 subjects; overall, the largest proportion of patients with B subtype (73.5%) acquired HIV-1 infection in South America., Conclusions: Our results indicated that South American transgenders largely contribute to the heterogeneity of HIV-1 variants in our country. The high number of clusters based on all subtypes indicated numerous transmission chains in which TSWs were constantly intermixed with HEs and MSM. Our results strongly advocate interventions to facilitate prevention, diagnosis and HIV-1 care continuum among transgender people., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
4. Effects of guggulsterones-containing thermogenic complex on elvitegravir plasma concentrations: a case report.
- Author
-
Cattaneo D, Ridolfo A, Baldelli S, and Gervasoni C
- Subjects
- Anti-HIV Agents pharmacokinetics, Anti-HIV Agents therapeutic use, CD4-Positive T-Lymphocytes drug effects, Cytochrome P-450 CYP3A metabolism, Drug Interactions, HIV Infections drug therapy, HIV Infections immunology, HIV Infections virology, Humans, Lymphocyte Count, Male, Middle Aged, Quinolones pharmacokinetics, Quinolones therapeutic use, RNA, Viral blood, Anti-HIV Agents blood, HIV Infections blood, Pregnenediones pharmacology, Quinolones blood
- Published
- 2019
- Full Text
- View/download PDF
5. How relevant are the drug-drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life?
- Author
-
Cattaneo D, Formenti T, Astuti N, Meraviglia P, Ridolfo A, and Gervasoni C
- Subjects
- Aged, Anti-Retroviral Agents administration & dosage, Calcium Channel Blockers administration & dosage, Cobicistat administration & dosage, Cobicistat pharmacology, Female, HIV Infections complications, Humans, Hypertension complications, Male, Middle Aged, Retrospective Studies, Ritonavir administration & dosage, Ritonavir pharmacology, Anti-Retroviral Agents pharmacology, Calcium Channel Blockers pharmacology, Drug Interactions, HIV Infections drug therapy, Hypertension drug therapy
- Published
- 2018
- Full Text
- View/download PDF
6. Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease.
- Author
-
Borges ÁH, Lundgren JD, Ridolfo A, Katlama C, Antunes F, Grzeszczuk A, Blaxhult A, Mitsura VM, Doroana M, Battegay M, Gargalianos P, and Mocroft A
- Subjects
- Adolescent, Adult, Aged, Cohort Studies, Female, Follow-Up Studies, Humans, Incidence, Male, Middle Aged, Prospective Studies, Risk Assessment, Young Adult, HIV Infections complications, HIV Infections drug therapy, Neoplasms epidemiology, Thrombocytopenia complications
- Abstract
Objective: To assess the relationship between platelet counts and risk of AIDS and non-AIDS-defining events., Design: Prospective cohort., Methods: EuroSIDA patients with at least one platelet count were followed from baseline (first platelet ≥ 1 January 2005) until last visit or death. Multivariate Poisson regression was used to assess the relationship between current platelet counts and the incidence of non-AIDS-defining (pancreatitis, end-stage liver/renal disease, cancer, cardiovascular disease) and AIDS-defining events., Results: There were 62 898 person-years of follow-up (PYFU) among 12 279 patients, including 1168 non-AIDS-defining events [crude incidence 18.6/1000 PYFU, 95% confidence interval (CI) 17.5-19.6] and 735 AIDS-defining events (crude incidence 11.7/1000 PYFU, 95% CI 10.8-12.5). Patients with thrombocytopenia (platelet count ≤100 × 10/l) had a slightly increased incidence of AIDS-defining events [adjusted incidence rate ratio (aIRR) 1.42, 95% CI 1.07-1.86], when compared to those with platelet counts 101-200 × 10/l, whereas the incidence of non-AIDS-defining events was more than two-fold higher (aIRR 2.66, 95% CI 2.17-3.26). Among non-AIDS-defining events, the adjusted incidence of cancer (aIRR 2.20, 95% CI 1.61-3.01), but not cardiovascular disease (aIRR 0.66, 95% CI 0.32-1.34), was significantly higher in patients with thrombocytopenia. The association between thrombocytopenia and cancer remained unaltered in sensitivity analyses requiring repeated platelet counts to confirm thrombocytopenia and lagging platelets by 1 year prior to clinical events., Conclusion: Patients with thrombocytopenia had increased incidence of AIDS-defining and non-AIDS-defining events, but the association with the latter, in particular cancer, was stronger. Future studies should investigate whether the pathophysiological processes underlying thrombocytopenia are associated with the development of cancer during treated HIV disease.
- Published
- 2014
- Full Text
- View/download PDF
7. Pancreatic cancer in HIV-positive patients: a clinical case-control study.
- Author
-
Zanet E, Berretta M, Benedetto FD, Talamini R, Ballarin R, Nunnari G, Berretta S, Ridolfo A, Lleshi A, Zanghì A, Cappellani A, and Tirelli U
- Subjects
- Adult, Age of Onset, Aged, Anti-HIV Agents therapeutic use, Antineoplastic Agents therapeutic use, Antiretroviral Therapy, Highly Active statistics & numerical data, Case-Control Studies, Comorbidity, Female, HIV Infections drug therapy, HIV Infections mortality, Humans, Incidence, Italy epidemiology, Male, Middle Aged, Multivariate Analysis, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms mortality, Retrospective Studies, Severity of Illness Index, HIV Infections epidemiology, Pancreatic Neoplasms epidemiology
- Abstract
Objectives: Pancreatic cancer (PC) is the fourth and fifth most common cause of cancer-related death among men in United States and in Europe, respectively. No data are available for HIV-positive patients. The aim of this study was to investigate and to compare clinical presentation and outcome between HIV-positive and HIV-negative PC patients., Methods: From April 1988 to June 2010, the Italian Cooperative Group on AIDS and Tumors identified 16 cases of HIV-positive PC patients. Each HIV-positive patient from our institution was randomly matched (ratio 1:2) with HIV-negative patients (32 controls) based on sex and year of PC diagnosis. Differences in clinical presentation, treatment, and overall survival were assessed., Results: At multivariate analysis, HIV-positive patients compared with HIV-negative patients had a higher risk of an unfavorable performance status (PS ≥ 2) and a younger age (<50 years) at cancer diagnosis. At multivariate analysis, HIV-positive status and PS of 2 or greater were the only 2 features that significantly reduced PC patients' survival., Conclusions: Our data show, for the first time, that HIV-positive PC patients, compared with HIV-negative patients, are younger at cancer diagnosis. Furthermore, they share a more unfavorable PS and a shorter survival.
- Published
- 2012
- Full Text
- View/download PDF
8. Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection.
- Author
-
Berretta M, Lleshi A, Cappellani A, Bearz A, Spina M, Talamini R, Cacopardo B, Nunnari G, Montesarchio V, Izzi I, Lanzafame M, Nasti G, Basile F, Berretta S, Fisichella R, Schiantarelli C C, Garlassi E, Ridolfo A, Guella L, and Tirelli U
- Subjects
- Adult, Anti-HIV Agents adverse effects, Antineoplastic Agents adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antiretroviral Therapy, Highly Active adverse effects, Antiretroviral Therapy, Highly Active methods, Colorectal Neoplasms secondary, Drug Therapy methods, Drug-Related Side Effects and Adverse Reactions, Female, Fluorouracil adverse effects, Fluorouracil therapeutic use, Humans, Italy, Leucovorin adverse effects, Leucovorin therapeutic use, Male, Middle Aged, Organoplatinum Compounds adverse effects, Organoplatinum Compounds therapeutic use, Treatment Outcome, Anti-HIV Agents therapeutic use, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms complications, Colorectal Neoplasms drug therapy, HIV Infections complications, HIV Infections drug therapy
- Abstract
Background: Although FOLFOX4 is considered the standard chemotherapy regimen for colorectal cancer (CRC), few data are available on its results in human immunodeficiency (HIV)-related CRC. The results were analyzed to evaluate feasibility and activity of FOLFOX4 plus highly active antiretroviral therapy (HAART) in metastatic CRC (mCRC) HIV-seropositive patients., Patients and Methods: From January 2002 to March 2007, 24 patients were selected among the CRC HIV-seropositive patients treated with FOLFOX4 and concomitant HAART within the Italian Cooperative Group on AIDS and Tumors (GICAT)., Results: Four median cycles of chemotherapy were administered; the most common severe toxicity was neutropenia (37.5%). An overall response rate of 50% was observed; 4.2% of patients achieved complete response and 45.8% partial response. No opportunistic infections occurred during or immediately after chemotherapy. The median CD4+ count was 380 (range 220-570) at diagnosis., Conclusions: To our knowledge, this is the largest study describing activity and tolerability of FOLFOX4 and HAART, in this setting. FOLFOX4 plus concomitant HAART resulted feasible and active also in HIV-seropositive patients. Moreover, the concomitant use of HAART did not to seem to increase the FOLFOX4 toxicity. This study suggests the good tolerability of the FOLFOX4, making it a reasonable option for combination with HAART.
- Published
- 2010
- Full Text
- View/download PDF
9. High prevalence of human T-lymphotropic virus type 1 (HTLV-1) in immigrant male-to-female transsexual sex workers with HIV-1 infection.
- Author
-
Zehender G, Colasante C, De Maddalena C, Bernini F, Savasi V, Persico T, Merli S, Ridolfo A, Santambrogio S, Moroni M, and Galli M
- Subjects
- Adult, Female, HIV Infections epidemiology, Human T-lymphotropic virus 1 classification, Human T-lymphotropic virus 1 genetics, Humans, Male, Molecular Epidemiology, Molecular Sequence Data, Phylogeny, Polymerase Chain Reaction, Prevalence, Sequence Analysis, DNA, Emigration and Immigration, HIV Infections complications, HTLV-I Infections epidemiology, Human T-lymphotropic virus 1 isolation & purification, Sex Work, Transsexualism
- Abstract
Human T-lymphotropic virus type 1 and 2 (HTLV-1 and HTLV-2) infections in Europe are limited to intravenous drug users and migrants coming from areas in which they are endemic. A survey was undertaken of HTLV-1 and HTLV-2 infections in 393 recent immigrants: 167 HIV-1 positive subjects (including 52 male-to-female transsexual sex workers) and 226 pregnant HIV-1 negative women. The prevalence of HTLV-1 was 3.6% in the HIV-1 positive group and 0.9% in the HIV-1 negative group. The highest HTLV-1 prevalence in both groups was found in persons from Latin America, particularly those born in Peru (up to 26% in the HIV-1 positive group). All of the HIV-1/HTLV-1 co-infected individuals were male-to-female transsexual sex workers in whom the overall prevalence of HTLV-1 infection was 11.5%. HTLV-2 was only found in the HIV-1 positive group (prevalence 1.2%); all of the infected subjects were transsexual sex workers from Brazil (overall prevalence 6.4%). Phylogenetic analysis showed that all of the HTLV-1 isolates were of the cosmopolitan type, clustering with other strains circulating in the patients' birthplaces; the HTLV-2 isolates were of subtype 2a, and clustered significantly with other Brazilian strains. These results suggest the independent origin of each infection in the patient's birthplace. The data raise concerns about the further spread of HTLV infections mainly through the sexual route.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.